Clinical trials: Liver Inflammation
Rift Valley Fever
Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003)
The goal of this clinical trial is to learn if ChAdOx1 RVF, a candidate vaccine against RVF, provides an adequate immune response and determine its safety among Kenyan adults.
- Trial name
- RVF003 (NCT06799234)
- Testing
- ChAdOx1 RVF, Rabies Vaccine
- Where
- Kenya
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Oxford
HIV/HCV Co-infection, HIV Infections
Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r
The aim of this study is to assess the efficacy of lopinavir/r in monotherapy and peg-interferon plus ribavirin for the control of both HIV and HCV infection respectively after 12 months of active treatment for HCV.
- Trial name
- PEKARI (NCT00866021)
- Testing
- Lopinavir/ritonavir, Lopinavir/ritonavir with two nucleoside analogs
- Where
- 10 sites in Spain
- Volunteers
- 68 people
- Sponsor
- Fundacion SEIMC-GESIDA
Hepatitis B, Chronic
A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection
The purpose of this study is to evaluate the efficacy of a treatment regimen of JNJ-73763989 + pegylated interferon alpha-2a (PegIFN-alpha-2a) + nucleos(t)ide analog (NA).
- Trial name
- NCT04439539
- Testing
- JNJ-73763989, PegIFN-alpha-2a, Tenofovir disoproxil
- Where
- 47 sites in United States, Canada and 8 more
- Volunteers
- 54 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Hepatitis B
Efficacy of HBV Vaccine in Consolidation of Nucleos(t)Ide Analogues Therapy
Background and aims: Nucleos(t)ide analogues may suppress HBV DNA to undetectable level, but only about 30-40% remain sustained response 1-3 years after discontinued therapy.
- Trial name
- NCT02505009
- Testing
- Engerix-B, Tenofovir, Entecavir
- Where
- Taiwan
- Volunteers
- 116 people
- Sponsor
- Chang Gung Memorial Hospital
Alcoholic Hepatitis
Alcoholic Hepatitis: A Multicenter, Observational Study by the TREAT Consortium
To conduct a prospective, multicenter, observational study of patients with well-characterized alcoholic hepatitis (AH) and frequency matched individuals (by age, gender, and race) with comparable history of alcohol consumption…
- Trial name
- NCT02172898
- Where
- 2 sites in United States
- Volunteers
- 454 people
- Sponsor
- Indiana University
Hepatitis D
A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D
The goal of this clinical trial is to evaluate the efficacy and safety of L47 in the treatment of chronic hepatitis D. Patients with compensated CHD who satisfy the eligibility criteria are stratified by the presence or absence…
- Trial name
- L47-HD-MN (NCT06505928)
- Testing
- hepalatide
- Where
- 2 sites in Mongolia
- Volunteers
- 90 people
- Sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
Chronic Hepatitis B, AgHbs Negativation
A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B
The purpose of this study is to assess the loss of HbsAg after a 48-week pegylated interferon alpha 2a in patients with chronic hepatitis B (HBeAg negativation)
- Trial name
- PEGAN (NCT01172392)
- Testing
- Pegylated interferon-alpha-2a, Nucleotidic or Nucleosidic Treatment
- Where
- France
- Volunteers
- 185 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis, Hepatitis C
An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C
The purpose of the study is to demonstrate the noninferiority of Algeron in combination with ribavirin compared to Pegasys in combination with ribavirin in the treatment of chronic hepatitis C.
- Trial name
- NCT01889433
- Testing
- Algeron, Pegasys
- Where
- 19 sites in Belarus, India and 2 more
- Volunteers
- 170 people
- Sponsor
- Biocad
Hepatitis C Virus Infection, Response to Therapy of
Safety & Efficacy of Sofosbuvir 400mg/Ledipasvir 90mg in the Treatment of Chronic Hepatitis C Adolescents
Randomized, open-label study in treatment naïve and treatment experienced, adolescence to determine the efficacy of Sofosbuvir 400mg/ledipasvir 90mg in treatment naïve and treatment-experienced adolescence.
- Trial name
- NCT03343444
- Testing
- 12 weeks (Sofosbuvir 400mg/Ledipasvir 90mg), 8 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Egyptian Liver Hospital
HIV Infections, Hepatitis C
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
HIV and hepatitis C virus (HCV) infection are diseases that share the same risk factors and routes of transmission. For this reason, many people infected with HIV are also infected with HCV.
- Trial name
- C_ASCENT (NCT02194998)
- Testing
- Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), Dasabuvir (DSV), Ribavirin (RBV)
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 46 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B
Immunogenicity and Safety of an Adjuvanted HBV Vaccine Compared to Engerix™-B, in a Non-responder Population ≥ 15y
Subjects who had not responded to previous hepatitis B vaccination were vaccinated with either the adjuvanted HBV-MPL vaccine or Engerix™-B vaccine according to a three-dose vaccination schedule (0, 1, 2 months) and boosted at…
- Trial name
- NCT00698061
- Testing
- HBV-MPL vaccine 208129, Engerix™-B
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C Virus Infection
Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) with or without ribavirin (RBV) in adults with chronic…
- Trial name
- NCT02472886
- Testing
- LDV/SOF, RBV
- Where
- 20 sites in Estonia, Russia
- Volunteers
- 153 people
- Sponsor
- Gilead Sciences
Hepatic Encephalopathy, Cirrhosis, Liver
Integrated Traditional Chinese and Clinical Medicine for Chronic Hepatitis B and Its Complication
Hepatic encephalopathy is the most common complication after TIPS, and hepatic encephalopathy occurs in almost all portosystemic shunts.
- Conditions
- Hepatic Encephalopathy, Cirrhosis, Liver, Portosystemic Shunt
- Trial name
- NCT05128305
- Testing
- traditional Chinese medicine1 and traditional Chinese medicine 2
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Qianfoshan Hospital
Hepatocellular Carcinoma
Epigenetic Changes in Hepatocellular Carcinoma Developed After Direct Acting Antiviral Therapy for Chronic Hepatitis C
Hepatocellular carcinoma (HCC) is the most common type of liver cancer, its survival rate ranks only second to lung cancer and it is a severe threat to human health. In Egypt, HCC constitutes a significant public health problem.
- Trial name
- NCT04220151
- Testing
- DNA methylation
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Chronic Hepatitis Delta Virus Infection
Expanded Access for Bulevirtide
The goal of this study is to provide access to bulevirtide (BLV (GS-4438), Hepcludex®) to eligible participants with chronic hepatitis delta virus infection (CHD).
- Trial name
- NCT06780579
- Testing
- Bulevirtide
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic, Chronic Renal Failure
Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir
Sofosbuvir is the base of most treatment regimens for hepatitis C. In patients with renal failure the blood level of one of its metabolites (GS-331007) rises up to 20 folds.
- Trial name
- SD-CRF (NCT03063879)
- Testing
- Sofosbuvir 400 mg and daclatasvir 60 mg
- Where
- Iran
- Volunteers
- 95 people
- Sponsor
- Tehran University of Medical Sciences
Chronic Hepatitis C
A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers
This is an open-label, two-group, fixed-sequence study to evaluate the effect of ACH-3102 and Simeprevir on AL-335 pharmacokinetics in healthy volunteers.
- Trial name
- NCT02512562
- Testing
- AL-335, ACH-3102, Simeprevir
- Where
- France
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Hepatitis C, Chronic
A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)
This study will provide vaniprevir 600 mg or 300 mg twice daily in combination with pegylated interferon (peg-IFN) and ribavirin (RBV) to participants with chronic hepatitis C virus (HCV) infection who did not achieve viral…
- Trial name
- NCT00943761
- Testing
- Vaniprevir 600 mg b.i.d., Vaniprevir 300 mg b.i.d., Pegylated interferon
- Volunteers
- 45 people
- Sponsor
- Merck Sharp & Dohme LLC
Renal Insufficiency
Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction
Renal dysfunction in the context of liver transplantation is a major issue, with difficult patients' management and determining a worsened prognosis.
- Trial name
- ATG_HVH (NCT01453218)
- Testing
- ATeGe-Fresenius
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Hospital Vall d'Hebron
HBeAg Positive Chronic Hepatitis B
Study on Antiviral Therapy for HBeAg-positive Chronic Hepatitis B Patients Aged 1-16 Years
The purpose of this study is to provide theoretical and real world evidence for the optimization of antiviral treatment by IFN combined with Nucleosides analog in HBeAg positive chronic hepatitis B patients aged 1-16 years，so…
- Trial name
- NCT04565262
- Testing
- NAs+IFN-α
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing 302 Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.